Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tetracycline-containing medicine composition and application for same

A composition and technology of tetracycline, applied in the field of medicine, can solve the problems of missed treatment period, treatment cost, timely diagnosis and prevention of cancer, etc.

Inactive Publication Date: 2014-07-23
NORTHWEST A & F UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The high cost of treatment prevents low- and middle-income people from timely diagnosis and prevention of cancer, thus missing the best treatment period, and even giving up treatment prematurely because they cannot afford the high cost of treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tetracycline-containing medicine composition and application for same
  • Tetracycline-containing medicine composition and application for same
  • Tetracycline-containing medicine composition and application for same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Example 1: In vitro study evaluating the effect of the combination of tetracycline and bortezomib on the growth of lung cancer cells.

[0052] Cell Culture: The NSCLC cell line tested in the experiments was A549 cells obtained from ATCC. The cell culture medium used was RPMI medium 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U / mL penicillin and 100 μg / mL streptomycin at 37 °C with a volume fraction of 5% CO 2 When cultured in an incubator, the cells grew adherently, and the cells in the logarithmic growth phase were used in the experiments.

[0053] Screening is done in two parts:

[0054] a. In the first set of experiments, the half inhibitory concentration (IC) of each drug was determined after being exposed to the A549 cell line for 72 hours 50 )value. Specific steps are as follows:

[0055] The logarithmic phase cells were collected, seeded in a 96-well plate, 100 μL was added to each well, and the concentration of the cell suspension was adj...

Embodiment 2

[0070] Example 2: In vitro study evaluating the effect of the combination of tetracycline and fludarabine on the growth of lung cancer cells.

[0071] Cells were cultured using the same method as in Example 1. Screening is done in two parts:

[0072] a. In the first group of experiments, using the same method as in Example 1, the half maximal inhibitory concentration (IC) of each drug was measured after being exposed to the A549 cell line for 72 hours. 50 )value. Draw a dose-response curve (Figure 1).

[0073] Table 4 provides the IC for each single agent in the combination of tetracycline and fludarabine 50 value.

[0074] Table 4

[0075] drug name

IC 50 (μM)

Tetracycline

42.8539

Fludarabine

0.25002

[0076] b. In the second set of experiments, using the same method as in Example 1, the inhibitory effect of tetracycline combined with fludarabine on the A549 cell line was determined ( FIG. 2 ).

[0077] Table 5 provides the C...

Embodiment 3

[0085] Example 3: In vitro study evaluating the effect of the combination of tetracycline and imatinib on the growth of lung cancer cells.

[0086] Cells were cultured using the same method as in Example 1. Screening is done in two parts:

[0087] b. In the first set of experiments, use the same method as in Example 1 to measure the half inhibitory concentration (IC) of each drug after being exposed to the A549 cell line for 72 hours. 50 )value. Draw a dose-response curve (Figure 1).

[0088] Table 7 provides the IC for each single agent in the combination of tetracycline and imatinib 50 value.

[0089] Table 7

[0090] drug name

IC 50 (μM)

Tetracycline

42.8539

Imatinib

50.1017

[0091] b. In the second set of experiments, using the same method as in Example 1, the inhibitory effect of tetracycline combined with imatinib on the A549 cell line was determined ( FIG. 2 ).

[0092] Table 8 provides the Combination Index (CI) obta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine composition. The medicine composition is a combination of tetracycline and at least one anti-cancer medicine selected from bortezomib, fludarabine, imatinib, cis-platinum and adriamycin amycin. The invention further discloses an application of the combinations in preparation of medicines for treating non-small cell lung cancer.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to a pharmaceutical composition formed of tetracycline and other anticancer drugs for the treatment of non-small cell lung cancer, especially selected from bortezomib, fludarabine, imatinib, cisplatin and A combination of other cancer drugs such as doxorubicin. Background technique [0002] Lung cancer is the number one killer of cancer patients in the world. Due to the delay in its diagnosis, the number of patients who die from lung cancer is as high as 1.38 million every year, accounting for 18% of all malignant tumor deaths. In my country, this figure is even higher. The results of the "Third National Cause of Death Survey" show that in the past 30 years, the mortality rate of lung cancer accounted for 22.7% of all malignant tumor deaths, an increase of 465%. Taking Beijing as an example, the incidence of lung cancer increased by 56% from 2001 to 2010. The World Health Organiz...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/05A61K31/69A61K33/24A61K31/65A61K31/7076A61K31/704A61P35/00A61K31/506
Inventor 王永华武子寅李鹏李丕栋夏效东汪纪楠周伟
Owner NORTHWEST A & F UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com